AXSM supply chain intelligence for Axsome Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Axsome Therapeutics, Inc. (AXSM) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| JAZZ | Jazz Pharmaceuticals plc | 90% | Pursuant to the Purchase Agreement, the Company agreed to make non-refundable, non-creditable royalty payments to Jazz |
| JAZZ | Jazz Pharmaceuticals plc | 90% | Reciprocal relationship from JAZZ graph: Reciprocal relationship from AXSM graph: Pursuant to the Purchase Agreement, the Company agreed to make non-refundable, non-creditable royalty payments to Jazz |
| AERIAL | AERIAL | 85% | At the Initial Closing, the Company assumed all of the commitments of Jazz to SK and Aerial. |
| FBIO | Fortress Biotech, Inc. | 72% | Reciprocal relationship from FBIO graph: Reciprocal relationship from AXSM graph: Reciprocal relationship from FBIO graph: Reciprocal relationship from AXSM graph: Reciprocal relationship from FBIO g… |
| FBIOP | FBIOP | 72% | Reciprocal relationship from FBIOP graph: Zeneca plc as successor-in-interest to Alexion Pharmaceuticals, Inc. (“AstraZeneca”), Sentynl Therapeutics, Inc. (“Sentynl”), Axsome Therapeutics, Inc. (“Axs… |
| IGC | IGC Pharma, Inc. | 72% | Reciprocal relationship from IGC graph: ing growth of the Life Sciences segment. These investments will fuel the development and delivery of innovative products that drive positive patient and custom… |
| TNXP | Tonix Pharmaceuticals Holding Corp. | 72% | Reciprocal relationship from TNXP graph: arket strategy. Our commercialization strategy for TONMYA is centered on a cost-efficient, targeted sales and marketing approach focused on the top prescribin… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| PHARMANOVIA | PHARMANOVIA | 92% | The Company also sells SUNOSI to Distributors in Canada and on a product supply basis to Pharmanovia. |
| IGC | IGC Pharma, Inc. | 72% | Reciprocal relationship from IGC graph: ing growth of the Life Sciences segment. These investments will fuel the development and delivery of innovative products that drive positive patient and custom… |
| JAZZ | Jazz Pharmaceuticals plc | 72% | Reciprocal relationship from JAZZ graph: Reciprocal relationship from AXSM graph: 1,572 Segment net loss $ ( 64,542 ) $ ( 59,413 ) Reconciliation of net loss Adjustments and reconciling items — — Con… |
| JAZZ | Jazz Pharmaceuticals plc | 72% | 1,572 Segment net loss $ ( 64,542 ) $ ( 59,413 ) Reconciliation of net loss Adjustments and reconciling items — — Consolidated net loss $ ( 64,542 ) $ ( 59,413 ) (a) Other research and development ex… |
| LLY | Eli Lilly and Company | 72% | DA issued more than 100 enforcement letters to pharmaceutical companies and compounding firms, alleging that certain promotional communications and DTC advertisements are false and misleading. Furthe… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from AXSM graph: DA issued more than 100 enforcement letters to pharmaceutical companies and compounding firms, alleging that certain p… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | . Note 15. Acquisitions In the first quarter of 2026, the Company acquired the global rights to balipodect (AXS-20), a selective PDE10A Inhibitor for the treatment of Schizophrenia and other neuropsy… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | Reciprocal relationship from TKPHF graph: Reciprocal relationship from AXSM graph: Reciprocal relationship from TKPHF graph: Reciprocal relationship from AXSM graph: . Note 15. Acquisitions In the fi… |
| TNXP | Tonix Pharmaceuticals Holding Corp. | 72% | Reciprocal relationship from TNXP graph: Reciprocal relationship from AXSM graph: Reciprocal relationship from TNXP graph: Reciprocal relationship from AXSM graph: Reciprocal relationship from TNXP g… |
| XENE | Xenon Pharmaceuticals Inc. | 72% | Reciprocal relationship from XENE graph: velopment and marketing efforts of our collaborators. • Our reliance on third parties to manufacture our product candidates may increase the risk that we will… |
| ATNAHS-PHARMA-UK-LIMITED | ATNAHS-PHARMA-UK-LIMITED | 62% | 1,572 Segment net loss $ ( 64,542 ) $ ( 59,413 ) Reconciliation of net loss Adjustments and reconciling items — — Consolidated net loss $ ( 64,542 ) $ ( 59,413 ) (a) Other research and development ex… |
| SK-BIOPHARMACEUTICALS-CO-LTD | SK-BIOPHARMACEUTICALS-CO-LTD | 62% | 1,572 Segment net loss $ ( 64,542 ) $ ( 59,413 ) Reconciliation of net loss Adjustments and reconciling items — — Consolidated net loss $ ( 64,542 ) $ ( 59,413 ) (a) Other research and development ex… |
| XIX-BIO-LLC | XIX-BIO-LLC | 62% | . Any change in our manufacturers could be costly because the commercial terms of any new arrangement could be less favorable and because the expenses relating to the transfer of necessary technology… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| AXSM-DEBT-8015 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2016-12-31. |
| AXSM-DEBT | Debt stack $188.0M | 90% | Market cache reports total debt of $188.0M. |
| AXSM-DEBT-8014 | Warrants outstanding: 56.8 | 90% | xbrl warrant detail from xbrl 2026-03-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| AXSM-OWNER-BLACKROCK-INC | BlackRock, Inc. | 90% | 13F overlay lists BlackRock, Inc. as top holder; 418 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| ACIU | AC Immune SA | 100.00 | 2 | |
| ACRS | Aclaris Therapeutics, Inc. | 100.00 | 2 | |
| SDGR | Schrödinger, Inc. | 100.00 | 2 | |
| BYSI | BeyondSpring Inc. | 100.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| CLYM | Climb Bio, Inc. | 100.00 | 2 | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 100.00 | 2 | |
| ALEC | Alector, Inc. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| AKTS | Aktis Oncology, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| DWTX | Dogwood Therapeutics, Inc. | 100.00 | 2 | |
| DFTX | Definium Therapeutics, Inc. | 100.00 | 2 | |
| EDSA | Edesa Biotech, Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| FHTX | Foghorn Therapeutics Inc. | 100.00 | 2 | |
| NVO | Novo Nordisk A/S | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| FDMT | 4D Molecular Therapeutics, Inc. | 100.00 | 2 |